US2016199323A1PendingUtilityA1

Cancer treatment

64
Assignee: VANDA PHARMACEUTICALS INCPriority: Aug 22, 2013Filed: Aug 22, 2014Published: Jul 14, 2016
Est. expiryAug 22, 2033(~7.1 yrs left)· nominal 20-yr term from priority
Inventors:Mihael H. PolymeropoulosLouis William LicameleChristian Lavedan
A61P 35/02A61P 35/00A61P 43/00C07K 2317/76A61K 2039/505C07K 2317/21C07K 2317/565A61K 38/00A61K 31/165A61K 9/08C07K 16/2866A61K 9/0019A61K 9/0053A61K 9/0095A61K 9/48A61K 9/107A61K 9/10
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating cancer in an individual, the method comprising:
 administering to the individual an effective amount of trichostatin A (TSA).   
     
     
         2 . The method of  claim 1 , wherein the effective amount is an amount sufficient to decrease an aurora kinase A (AURKA) level in the individual. 
     
     
         3 . The method of  claim 1 , wherein the effective amount is an amount sufficient to inhibit histone deacetylase (HDAC) activity and decrease an aurora kinase A (AURKA) level in the individual. 
     
     
         4 . The method of  claim 1 , wherein the effective amount is between about 0.1 mg/kg/day and about 10 mg/kg/day. 
     
     
         5 . The method of  claim 4 , wherein the effective amount is between about 0.5 mg/kg/day and about 5 mg/kg/day. 
     
     
         6 . The method of  claim 5 , wherein TSA is the only AURKA inhibitor administered to the individual. 
     
     
         7 . The method of  claim 1 , wherein the cancer includes at least one cancer selected from a group consisting of: breast cancer, gastric cancer, colon cancer, rectal cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, lung cancer, hematological cancer, skin cancer, and malignancies. 
     
     
         8 . The method of  claim 1 , wherein administering includes orally administering. 
     
     
         9 . The method of  claim 1 , wherein administering includes intravenously administering. 
     
     
         10 . A method of treating a cancer in an individual, the method comprising:
 determining, from a tumor sample obtained from the individual's body, a level of aurora kinase A (AURKA) expression; and   in the case that the level of AURKA expression is indicative of overexpression, administering to the individual an effective amount of trichostatin A (TSA).   
     
     
         11 . The method of  claim 10 , wherein the effective amount is an amount sufficient to decrease an aurora kinase A (AURKA) level in the individual. 
     
     
         12 . The method of  claim 10 , wherein the effective amount is an amount sufficient to inhibit histone deacetylase (HDAC) activity and decrease an aurora kinase A (AURKA) level in the individual. 
     
     
         13 . The method of  claim 10 , wherein the effective amount is between about 0.1 mg/kg/day and about 10 mg/kg/day. 
     
     
         14 . The method of  claim 13 , wherein the effective amount is between about 0.5 mg/kg/day and about 5 mg/kg/day. 
     
     
         15 . The method of  claim 10 , wherein TSA is the only AURKA inhibitor administered to the individual. 
     
     
         16 . The method of  claim 10 , wherein the cancer includes at least one cancer selected from a group consisting of: breast cancer, gastric cancer, colon cancer, rectal cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, lung cancer, hematological cancer, skin cancer, and malignancies. 
     
     
         17 . The method of  claim 10 , wherein administering includes orally administering. 
     
     
         18 . The method of  claim 10 , wherein administering includes intravenously administering. 
     
     
         19 . A pharmaceutical composition comprising:
 trichostatin A (TSA) as a sole or primary aurora kinase A (AURKA) inhibitor; and   a pharmaceutically-acceptable excipient or carrier.   
     
     
         20 . The pharmaceutical composition of  claim 19  formulated for oral administration. 
     
     
         21 . The pharmaceutical composition of  claim 19  formulated for intravenous administration. 
     
     
         22 . The pharmaceutical composition of  claim 19 , comprising TSA in an amount between about 1 mg and about 500 mg. 
     
     
         23 . The pharmaceutical composition of  claim 22 , wherein the amount of TSA is equivalent to a dose between about 0.1 mg/kg/day and about 10 mg/kg/day. 
     
     
         24 . The pharmaceutical composition of  claim 23 , wherein the amount of TSA is equivalent to a dose between about 0.5 mg/kg/day and about 5 mg/kg/day. 
     
     
         25 . The pharmaceutical composition of  claim 22 , wherein the amount of TSA is effective to inhibit histone deacetylase (HDAC) activity.

Join the waitlist — get patent alerts

Track US2016199323A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.